ASCO/CAP乳腺癌HER2检测指南聚焦更新
该指南更新了ASCO/CAP乳腺癌HER2检测的关键推荐,基于信号方法由专家小组审阅文献和调研结果,针对双探针ISH少见模式(约5%病例)更新检测流程,强调ISH与IHC联合判读以准确判定HER2状态。
要点
- IHC 2+定义为浸润性乳腺癌中>10%肿瘤细胞呈现弱至中等完整膜染色。
- 粗针穿刺活检HER2阴性时,可根据特定临床标准在切除标本上追加检测(非必须)。
- 双探针ISH第2–4组需联合IHC复核以准确判定HER2阳性或阴性。
核心结论
- 更新了乳腺癌HER2检测的关键推荐,涵盖IHC 2+定义、活检与切除标本检测衔接及双探针ISH少见模式的判读流程。
研究设计与样本
- 基于信号方法的专家小组更新,审阅已发表文献和调研结果,针对双探针ISH少见模式(约5%病例)修订推荐。
主要发现
- 双探针ISH少见模式分为第2组(HER2/CEP17比值≥2.0且平均HER2拷贝数<4.0信号/细胞)、第3组(比值<2.0且拷贝数≥6.0信号/细胞)和第4组(比值<2.0且拷贝数≥4.0且<6.0信号/细胞)。
关键数值与推荐
- IHC 2+定义为浸润性乳腺癌中>10%肿瘤细胞呈现弱至中等完整膜染色。
- 粗针穿刺活检HER2阴性时,可根据特定临床标准在切除标本上追加HER2检测(非必须)。
- 双探针ISH第2至4组需联合IHC复核,基于ISH与IHC联合判读得出最准确HER2状态。
- 使用单探针ISH检测的实验室应将同步IHC复核纳入所有单探针ISH结果的判读。
临床怎么用
- 病理实验室应按更新流程对双探针ISH第2至4组及单探针ISH结果进行同步IHC复核,以准确判定HER2状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 (HER2) testing in breast cancer guideline. Methods Based on the signals approach, an Expert Panel reviewed published literature and research survey results on the observed frequency of less common in situ hybridization (ISH) patterns to update the recommendations. Recommendations Two recommendations addressed via correspondence in 2015 are included. First, immunohistochemistry (IHC) 2+ is defined as invasive breast cancer with weak to moderate complete membrane staining observed in > 10% of tumor cells. Second, if the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test may (not "must") be ordered on the excision specimen based on specific clinical criteria. The HER2 testing algorithm for breast cancer is updated to address the recommended work-up for less common clinical scenarios (approximately 5% of cases) observed when using a dual-probe ISH assay. These scenarios are described as ISH group 2 ( HER2/chromosome enumeration probe 17 [CEP17] ratio ≥ 2.0; average HER2 copy number < 4.0 signals per cell), ISH group 3 ( HER2/CEP17 ratio < 2.0; average HER2 copy number ≥ 6.0 signals per cell), and ISH group 4 ( HER2/CEP17 ratio < 2.0; average HER2 copy number ≥ 4.0 and < 6.0 signals per cell). The diagnostic approach includes more rigorous interpretation criteria for ISH and requires concomitant IHC review for dual-probe ISH groups 2 to 4 to arrive at the most accurate HER2 status designation (positive or negative) based on combined interpretation of the ISH and IHC assays. The Expert Panel recommends that laboratories using single-probe ISH assays include concomitant IHC review as part of the interpretation of all single-probe ISH assay results. Find additional information at www.asco.org/breast-cancer-guidelines .
引用
- Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018. PMID: 29846122. doi:10.1200/JCO.2018.77.8738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。